Exelixis Director Sells $526K in Shares Under Planned Trade
Board member Mary Beckerle offloaded nearly 10,000 shares via a pre-set trading plan, even as Exelixis stock looks undervalued.
If you've been keeping tabs on insider activity at Exelixis, here's a move worth noting. Director Mary Beckerle recently sold 9,812 shares of the biotech company's common stock, pulling in just over $526,000 from the transaction. Before you read too much into it, the sale was executed under a Rule 10b5-1 trading plan — essentially a pre-scheduled arrangement that insiders set up in advance to avoid any appearance of trading on inside information.
After the dust settled, Beckerle still holds 16,079 shares beneficially, a figure that includes restricted stock units (RSUs). RSUs are a form of compensation that convert into actual shares once certain conditions are met, so she's not exactly walking away from the table empty-handed.
Read more Kimco Realty Raises Dividend 12% and Upgrades 2026 Earnings Outlook →
Timing-wise, the sale happened while Exelixis shares were going through a bit of a rough patch in recent trading. That said, the stock has still managed to post a strong return over the past year, so the longer-term picture hasn't exactly fallen apart. What makes this more interesting is that InvestingPro's analysis flags the stock as currently undervalued — meaning the market may not be fully pricing in what the company is worth right now.
For everyday investors, a planned insider sale doesn't automatically signal trouble. Executives and directors sell shares for all kinds of personal reasons — diversification, tax planning, big life expenses — and the 10b5-1 structure is specifically designed to remove any last-minute, opportunistic decision-making from the equation. Still, it's always smart to pair insider transaction data with broader fundamental research before drawing conclusions about where a stock is headed.
Continue reading at Investing.com
